Momenta Pharmaceuticals Stock News

Technically speaking, the U.S. benchmarks’ bigger-picture backdrop remains bullish, on balance, despite increasingly uneven market price action, writes...

The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) ADC Therapeutics SA (...

Two Sigma Advisers LP lifted its stake in shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 32.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securit

SunTrust Banks upgraded shares of Momenta Pharmaceuticals (NASDAQ:MNTA) to a buy rating in a research note released on Thursday, LiveTradingNews reports. SunTrust Banks also issued estimates for Momen

NAB's $2.35 billion wealth remediation program has run into trouble after Deloitte set up a separate low-cost delivery arm staffed by inexperienced graduates banned from saying they work for the big f

Geode Capital Management LLC raised its stake in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 16.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exc

Parametric Portfolio Associates LLC lifted its holdings in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 32.8% during the 1st quarter, according to its most recent disclosure with the SEC. The instit

Thousands of additional work-from-home financial services staff are needed by banks, insurers and credit card firms to help people deal with the impact of coronavirus on their finances, according to

Thousands of additional work-from-home financial services staff are needed by banks, insurers and credit card firms to help people deal with the impact of coronavirus on their finances, according to

As of late, it has definitely been a great time to be an investor in Momenta Pharmaceuticals, Inc. (MNTA).

Momenta Pharmaceuticals (NASDAQ:MNTA) had its target price upped by analysts at SunTrust Banks from $50.00 to $57.00 in a report issued on Wednesday, The Fly reports. SunTrust Banks’ price objective

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) – Investment analysts at Piper Sandler lowered their Q2 2020 earnings per share (EPS) estimates for shares of Momenta Pharmaceuticals in a note issued to

The

Not to be outdone by the biotechs battling COVID-19, shares of immune disease specialist Momenta Pharmaceuticals (MNTA) are up by a hefty 85% year-to-date. Monday’s session provided an additional 15

The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.